Vildagliptin has the same safety profile as a sulfonylurea on bone metabolism and bone mineral density in post-menopausal women with type 2 diabetes: a randomized controlled trial

Table 2 Baseline values and changes in bone remodeling marker values in vildagliptin and gliclazide MR treatment groups

Variables	Vildagliptin (N = 21)	Gliclazide MR (N = 21)	p value (among groups)
OC (ng/mL)
Baseline	12.5 ± 4.2	10.2 ± 3.5	0.063
Change from baseline to month 6	1.0 ± 3.5	0.5 ± 2.9	0.622
p value*	0.204	0.438
Change from baseline to month 12	−0.1 ± 2.9	0.6 ± 3.8	0.519
p value*	0.930	0.468
PINP (ng/mL)
Baseline	38.1 ± 11.8	36.3 ± 14.7	0.660
Change from baseline to month 6	2.4 ± 14.9	−0.3 ± 8.3	0.475
p value*	0.462	0.887
CTX (ng/mL)
Baseline	0.288 ± 0.139	0.197 ± 0.062	0.013
Change from baseline to month 6	0.010 ± 0.071	0.029 ± 0.052	0.355
p value*	0.523	0.023
Change from baseline to month 12	0.001 ± 0.153	0.008 ± 0.060	0.858
p value*	0.563	0.972
U-NTX (nmol/BCE/mmol creatinine)
Baseline	41.1 ± 16.5	35.6 ± 14.4	0.255
Change from baseline to month 6	8.1 ± 25.9	−2.2 ± 16.4	0.138
p value*	0.167	0.555
Change from baseline to month 12	−1.1 ± 25.8	−1.9 ± 19.3	0.902
p value*	0.854	0.660

Variables are expressed as the mean ± SD
OC osteocalcin, PINP amino-terminal propeptide of procollagen type 1, CTX carboxy-terminal telopeptide of type 1 collagen, U-NTX urinary amino-terminal telopeptide of type 1 collagen
* p value after therapy versus baseline

ISSN: 1758-5996